

# OVAPAR

**(Olaparib 100/150 mg Tab)**

*Recurrent & or advanced Ovarian cancer.*

**HER2 -negative High-risk early Breast cancer & MBC,**

**HRR gene mutated mCRPC, & BRCA-mutated mCRPC.**

*Pancreatic cancer,*

**Fallopian tube cancer, and Peritoneal cancer.**

**Dosage: 300 mg PO BID**



**The Numero Uno  
PARP inhibitor**



## MORE INFORMATION

+91 22 4801 6166 / +91 22 4616 6610

[www.mxmhealthcare.com](http://www.mxmhealthcare.com)

[assist@mxmhealthcare.com](mailto:assist@mxmhealthcare.com)

112,113,114 Crescent Business Park,  
Sakinaka Telephone exchange Lane.  
Andheri (East). Mumbai 400 072

# OVAPAR

(Olaparib 100/150 mg Tab)

## The Numero Uno

## PARP inhibitor

**OVAPAR** improves the outcome in **Metastatic Prostate Cancer**.

*The PORpel study showed a benefit in all patients irrespective of mutation status.*

**“The use of PARP Inhibitors (**OVAPAR**) as frontline maintenance in Ovarian Cancer is the absolute standard of care”<sup>2</sup>**

**OVAPAR** plus RT well tolerated in Triple-Negative Breast Cancer.<sup>3</sup>

- 1 Medscape Oncology 2023
- 2 BRCA Ovarian cancer in Neo adjuvant setting Medscape Oncology 2023.
- 3 JAMA Oncology 2022



Maximal Healthcare Pvt Ltd

